Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician's guide.

Abstract

INTRODUCTION:

PSMA-targeted PET/CT is a 'Next Generation Imaging' technique with superior sensitivity and specificity for detecting recurrent prostate cancer compared with conventional imaging, allowing more accurate staging and re-staging.

AREAS COVERED:

This article reviews the role of PSMA-targeted PET/CT in clinical management of men with recurrent prostate cancer.

EXPERT OPINION:

Through enhanced spatial characterization of recurrent prostate cancer, PSMA-targeted PET/CT has shown significant impact on management decisions. In particular, by identifying men with recurrence confined to the prostate or pelvic nodes, PSMA-targeted PET/CT enables selective deployment of localized salvage therapies for management of biochemical failure after primary treatment with prostatectomy or radiotherapy. In oligometastatic disease, PSMA-targeted PET/CT may improve patient selection and treatment accuracy for metastasis-directed therapy and early phase II studies show encouraging results in delaying the need for systemic therapy. Further, quantitative PSMA-targeted PET/CT for monitoring response and therapeutic PSMA-targeted radiopharmaceuticals are emerging as encouraging treatment options in the setting of castrate-resistant disease.

• Authors: Sympascho Young, Wei Liu, Katherine Zukotynski, Glenn Bauman
• Journal: Expert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 21 Issue 6 Pg. 641-655 (06 2021) ISSN: 1744-8328 [Electronic] England
• PMID: 33476253 (Publication Type: Journal Article, Review)

Chemical References

• Radiopharmaceuticals
• Prostate-Specific Antigen

Topics

• Humans
• Male
• Neoplasm Recurrence, Local (diagnostic imaging)
• Positron Emission Tomography Computed Tomography (methods)
• Prostate (pathology)
• Prostate-Specific Antigen
• Prostatectomy (methods)
• Prostatic Neoplasms (diagnostic imaging, pathology, therapy)
• Radiopharmaceuticals